OpenAccessBelV2, PascalFrancis, Corpus, bibRecord, 000058

20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers

Identifieur interne : 000058 ( PascalFrancis/Corpus ); précédent : 000057; suivant : 000059

20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers

Auteurs : Carsten Stephan ; Chris Bangma ; Giulio Vignati ; Georg Bartsch ; Michael Lein ; Klaus Jung ; Marianne Philippe ; Axel Semjonow ; William J. Catalona

Source :

The International journal of biological markers [ 0393-6155 ] ; 2009.

RBID : Pascal:09-0458278

Descripteurs français

Pascal (Inist)
- Biologie clinique, Analyse quantitative, Forme libre, Cancer de la prostate, Antigène spécifique prostate, Marqueur tumoral, Méthode immunologique, Etalonnage, Urologie, OMS, Matériau référence, Homme, Biochimie, Biologie moléculaire, Diagnostic, Total, Cancérologie.

English descriptors

KwdEn :
- Biochemistry, Calibration, Cancerology, Clinical biology, Diagnosis, Free form, Human, Immunological method, Molecular biology, Prostate cancer, Prostate specific antigen, Quantitative analysis, Reference material, Total, Tumoral marker, Urology, WHO.

Abstract

Aim: To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods: Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results: All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA x 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0393-6155`
A03		`1`		`@0 Int. j. biol. markers`
A05				`@2 24`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers`
A11	`01`	`1`		`@1 STEPHAN (Carsten)`
A11	`02`	`1`		`@1 BANGMA (Chris)`
A11	`03`	`1`		`@1 VIGNATI (Giulio)`
A11	`04`	`1`		`@1 BARTSCH (Georg)`
A11	`05`	`1`		`@1 LEIN (Michael)`
A11	`06`	`1`		`@1 JUNG (Klaus)`
A11	`07`	`1`		`@1 PHILIPPE (Marianne)`
A11	`08`	`1`		`@1 SEMJONOW (Axel)`
A11	`09`	`1`		`@1 CATALONA (William J.)`
A14	`01`			`@1 Department of Urology, Charité - Universitätsmedizin Berlin @2 Berlin @3 DEU @Z 1 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Urology, Erasmus Medical Center and University @2 Rotterdam @3 NLD @Z 2 aut.`
A14	`03`			`@1 Center of Endocrine and Metabolic Diseases, G. Fornaroli Hospital @2 Magenta @3 ITA @Z 3 aut.`
A14	`04`			`@1 Department of Urology, Medical University Innsbruck @2 Innsbruck @3 AUT @Z 4 aut.`
A14	`05`			`@1 Berlin Institute for Urologic Research @2 Berlin @3 DEU @Z 5 aut. @Z 6 aut.`
A14	`06`			`@1 Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc @2 Brussels @3 BEL @Z 7 aut.`
A14	`07`			`@1 Prostate Center, University Clinic Münster @3 DEU @Z 8 aut.`
A14	`08`			`@1 Department of Urology, Northwestern Feinberg School of Medicine @2 Chicago, IL @3 USA @Z 9 aut.`
A20				`@1 65-69`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21868 @5 354000171178220010`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 27 ref.`
A47	`01`	`1`		`@0 09-0458278`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The International journal of biological markers`
A66	`01`			`@0 ITA`
C01	`01`		`ENG`	@0 Aim: To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods: Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results: All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA x 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk.
C02	`01`	`X`		`@0 002B24O11`
C02	`02`	`X`		`@0 002B20B02`
C03	`01`	`X`	`FRE`	`@0 Biologie clinique @5 01`
C03	`01`	`X`	`ENG`	`@0 Clinical biology @5 01`
C03	`01`	`X`	`SPA`	`@0 Biología clínica @5 01`
C03	`02`	`X`	`FRE`	`@0 Analyse quantitative @5 02`
C03	`02`	`X`	`ENG`	`@0 Quantitative analysis @5 02`
C03	`02`	`X`	`SPA`	`@0 Análisis cuantitativo @5 02`
C03	`03`	`X`	`FRE`	`@0 Forme libre @5 03`
C03	`03`	`X`	`ENG`	`@0 Free form @5 03`
C03	`03`	`X`	`SPA`	`@0 Forma libre @5 03`
C03	`04`	`X`	`FRE`	`@0 Cancer de la prostate @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Prostate cancer @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Cáncer de la próstata @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Antigène spécifique prostate @5 05`
C03	`05`	`X`	`ENG`	`@0 Prostate specific antigen @5 05`
C03	`05`	`X`	`SPA`	`@0 Antigeno específico prostata @5 05`
C03	`06`	`X`	`FRE`	`@0 Marqueur tumoral @5 06`
C03	`06`	`X`	`ENG`	`@0 Tumoral marker @5 06`
C03	`06`	`X`	`SPA`	`@0 Marcador tumoral @5 06`
C03	`07`	`X`	`FRE`	`@0 Méthode immunologique @5 07`
C03	`07`	`X`	`ENG`	`@0 Immunological method @5 07`
C03	`07`	`X`	`SPA`	`@0 Método inmunológico @5 07`
C03	`08`	`X`	`FRE`	`@0 Etalonnage @5 08`
C03	`08`	`X`	`ENG`	`@0 Calibration @5 08`
C03	`08`	`X`	`SPA`	`@0 Contraste @5 08`
C03	`09`	`X`	`FRE`	`@0 Urologie @5 09`
C03	`09`	`X`	`ENG`	`@0 Urology @5 09`
C03	`09`	`X`	`SPA`	`@0 Urología @5 09`
C03	`10`	`X`	`FRE`	`@0 OMS @5 11`
C03	`10`	`X`	`ENG`	`@0 WHO @5 11`
C03	`10`	`X`	`SPA`	`@0 OMS @5 11`
C03	`11`	`X`	`FRE`	`@0 Matériau référence @5 12`
C03	`11`	`X`	`ENG`	`@0 Reference material @5 12`
C03	`11`	`X`	`SPA`	`@0 Material referencia @5 12`
C03	`12`	`X`	`FRE`	`@0 Homme @5 17`
C03	`12`	`X`	`ENG`	`@0 Human @5 17`
C03	`12`	`X`	`SPA`	`@0 Hombre @5 17`
C03	`13`	`X`	`FRE`	`@0 Biochimie @5 18`
C03	`13`	`X`	`ENG`	`@0 Biochemistry @5 18`
C03	`13`	`X`	`SPA`	`@0 Bioquímica @5 18`
C03	`14`	`X`	`FRE`	`@0 Biologie moléculaire @5 19`
C03	`14`	`X`	`ENG`	`@0 Molecular biology @5 19`
C03	`14`	`X`	`SPA`	`@0 Biología molecular @5 19`
C03	`15`	`X`	`FRE`	`@0 Diagnostic @5 20`
C03	`15`	`X`	`ENG`	`@0 Diagnosis @5 20`
C03	`15`	`X`	`SPA`	`@0 Diagnóstico @5 20`
C03	`16`	`X`	`FRE`	`@0 Total @5 21`
C03	`16`	`X`	`ENG`	`@0 Total @5 21`
C03	`16`	`X`	`SPA`	`@0 Total @5 21`
C03	`17`	`X`	`FRE`	`@0 Cancérologie @5 22`
C03	`17`	`X`	`ENG`	`@0 Cancerology @5 22`
C03	`17`	`X`	`SPA`	`@0 Cancerología @5 22`
C07	`01`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 37`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Pathologie de la prostate @5 38`
C07	`03`	`X`	`ENG`	`@0 Prostate disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Prostata patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'appareil génital mâle @5 39`
C07	`04`	`X`	`ENG`	`@0 Male genital diseases @5 39`
C07	`04`	`X`	`SPA`	`@0 Aparato genital macho patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 40`
C07	`05`	`X`	`ENG`	`@0 Urinary system disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Aparato urinario patología @5 40`
N21				`@1 334`

Format Inist (serveur)

NO :	PASCAL 09-0458278 INIST
ET :	20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers
AU :	STEPHAN (Carsten); BANGMA (Chris); VIGNATI (Giulio); BARTSCH (Georg); LEIN (Michael); JUNG (Klaus); PHILIPPE (Marianne); SEMJONOW (Axel); CATALONA (William J.)
AF :	Department of Urology, Charité - Universitätsmedizin Berlin/Berlin/Allemagne (1 aut., 5 aut., 6 aut.); Department of Urology, Erasmus Medical Center and University/Rotterdam/Pays-Bas (2 aut.); Center of Endocrine and Metabolic Diseases, G. Fornaroli Hospital/Magenta/Italie (3 aut.); Department of Urology, Medical University Innsbruck/Innsbruck/Autriche (4 aut.); Berlin Institute for Urologic Research/Berlin/Allemagne (5 aut., 6 aut.); Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc/Brussels/Belgique (7 aut.); Prostate Center, University Clinic Münster/Allemagne (8 aut.); Department of Urology, Northwestern Feinberg School of Medicine/Chicago, IL/Etats-Unis (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	The International journal of biological markers; ISSN 0393-6155; Italie; Da. 2009; Vol. 24; No. 2; Pp. 65-69; Bibl. 27 ref.
LA :	Anglais
EA :	Aim: To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods: Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results: All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA x 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk.
CC :	002B24O11; 002B20B02
FD :	Biologie clinique; Analyse quantitative; Forme libre; Cancer de la prostate; Antigène spécifique prostate; Marqueur tumoral; Méthode immunologique; Etalonnage; Urologie; OMS; Matériau référence; Homme; Biochimie; Biologie moléculaire; Diagnostic; Total; Cancérologie
FG :	Tumeur maligne; Cancer; Pathologie de la prostate; Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire
ED :	Clinical biology; Quantitative analysis; Free form; Prostate cancer; Prostate specific antigen; Tumoral marker; Immunological method; Calibration; Urology; WHO; Reference material; Human; Biochemistry; Molecular biology; Diagnosis; Total; Cancerology
EG :	Malignant tumor; Cancer; Prostate disease; Male genital diseases; Urinary system disease
SD :	Biología clínica; Análisis cuantitativo; Forma libre; Cáncer de la próstata; Antigeno específico prostata; Marcador tumoral; Método inmunológico; Contraste; Urología; OMS; Material referencia; Hombre; Bioquímica; Biología molecular; Diagnóstico; Total; Cancerología
LO :	INIST-21868.354000171178220010
ID :	09-0458278

Links to Exploration step

Pascal:09-0458278

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers</title>
<author><name sortKey="Stephan, Carsten" sort="Stephan, Carsten" uniqKey="Stephan C" first="Carsten" last="Stephan">Carsten Stephan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bangma, Chris" sort="Bangma, Chris" uniqKey="Bangma C" first="Chris" last="Bangma">Chris Bangma</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Urology, Erasmus Medical Center and University</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vignati, Giulio" sort="Vignati, Giulio" uniqKey="Vignati G" first="Giulio" last="Vignati">Giulio Vignati</name>
<affiliation><inist:fA14 i1="03"><s1>Center of Endocrine and Metabolic Diseases, G. Fornaroli Hospital</s1>
<s2>Magenta</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bartsch, Georg" sort="Bartsch, Georg" uniqKey="Bartsch G" first="Georg" last="Bartsch">Georg Bartsch</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Urology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lein, Michael" sort="Lein, Michael" uniqKey="Lein M" first="Michael" last="Lein">Michael Lein</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Berlin Institute for Urologic Research</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jung, Klaus" sort="Jung, Klaus" uniqKey="Jung K" first="Klaus" last="Jung">Klaus Jung</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Berlin Institute for Urologic Research</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Philippe, Marianne" sort="Philippe, Marianne" uniqKey="Philippe M" first="Marianne" last="Philippe">Marianne Philippe</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Semjonow, Axel" sort="Semjonow, Axel" uniqKey="Semjonow A" first="Axel" last="Semjonow">Axel Semjonow</name>
<affiliation><inist:fA14 i1="07"><s1>Prostate Center, University Clinic Münster</s1>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Catalona, William J" sort="Catalona, William J" uniqKey="Catalona W" first="William J." last="Catalona">William J. Catalona</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Urology, Northwestern Feinberg School of Medicine</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0458278</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0458278 INIST</idno>
<idno type="RBID">Pascal:09-0458278</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000058</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers</title>
<author><name sortKey="Stephan, Carsten" sort="Stephan, Carsten" uniqKey="Stephan C" first="Carsten" last="Stephan">Carsten Stephan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bangma, Chris" sort="Bangma, Chris" uniqKey="Bangma C" first="Chris" last="Bangma">Chris Bangma</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Urology, Erasmus Medical Center and University</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vignati, Giulio" sort="Vignati, Giulio" uniqKey="Vignati G" first="Giulio" last="Vignati">Giulio Vignati</name>
<affiliation><inist:fA14 i1="03"><s1>Center of Endocrine and Metabolic Diseases, G. Fornaroli Hospital</s1>
<s2>Magenta</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bartsch, Georg" sort="Bartsch, Georg" uniqKey="Bartsch G" first="Georg" last="Bartsch">Georg Bartsch</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Urology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lein, Michael" sort="Lein, Michael" uniqKey="Lein M" first="Michael" last="Lein">Michael Lein</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Berlin Institute for Urologic Research</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jung, Klaus" sort="Jung, Klaus" uniqKey="Jung K" first="Klaus" last="Jung">Klaus Jung</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Berlin Institute for Urologic Research</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Philippe, Marianne" sort="Philippe, Marianne" uniqKey="Philippe M" first="Marianne" last="Philippe">Marianne Philippe</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Semjonow, Axel" sort="Semjonow, Axel" uniqKey="Semjonow A" first="Axel" last="Semjonow">Axel Semjonow</name>
<affiliation><inist:fA14 i1="07"><s1>Prostate Center, University Clinic Münster</s1>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Catalona, William J" sort="Catalona, William J" uniqKey="Catalona W" first="William J." last="Catalona">William J. Catalona</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Urology, Northwestern Feinberg School of Medicine</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The International journal of biological markers</title>
<title level="j" type="abbreviated">Int. j. biol. markers</title>
<idno type="ISSN">0393-6155</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The International journal of biological markers</title>
<title level="j" type="abbreviated">Int. j. biol. markers</title>
<idno type="ISSN">0393-6155</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biochemistry</term>
<term>Calibration</term>
<term>Cancerology</term>
<term>Clinical biology</term>
<term>Diagnosis</term>
<term>Free form</term>
<term>Human</term>
<term>Immunological method</term>
<term>Molecular biology</term>
<term>Prostate cancer</term>
<term>Prostate specific antigen</term>
<term>Quantitative analysis</term>
<term>Reference material</term>
<term>Total</term>
<term>Tumoral marker</term>
<term>Urology</term>
<term>WHO</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Biologie clinique</term>
<term>Analyse quantitative</term>
<term>Forme libre</term>
<term>Cancer de la prostate</term>
<term>Antigène spécifique prostate</term>
<term>Marqueur tumoral</term>
<term>Méthode immunologique</term>
<term>Etalonnage</term>
<term>Urologie</term>
<term>OMS</term>
<term>Matériau référence</term>
<term>Homme</term>
<term>Biochimie</term>
<term>Biologie moléculaire</term>
<term>Diagnostic</term>
<term>Total</term>
<term>Cancérologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aim: To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods: Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results: All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA x 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0393-6155</s0>
</fA01>
<fA03 i2="1"><s0>Int. j. biol. markers</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>STEPHAN (Carsten)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BANGMA (Chris)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VIGNATI (Giulio)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BARTSCH (Georg)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LEIN (Michael)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>JUNG (Klaus)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>PHILIPPE (Marianne)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SEMJONOW (Axel)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CATALONA (William J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Urology, Charité - Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Urology, Erasmus Medical Center and University</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Center of Endocrine and Metabolic Diseases, G. Fornaroli Hospital</s1>
<s2>Magenta</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Urology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Berlin Institute for Urologic Research</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Prostate Center, University Clinic Münster</s1>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Urology, Northwestern Feinberg School of Medicine</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>65-69</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21868</s2>
<s5>354000171178220010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>27 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0458278</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The International journal of biological markers</s0>
</fA64>
<fA66 i1="01"><s0>ITA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Aim: To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods: Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results: All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA x 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24O11</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Biologie clinique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Clinical biology</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Biología clínica</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Analyse quantitative</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Quantitative analysis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Análisis cuantitativo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Forme libre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Free form</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Forma libre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cancer de la prostate</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prostate cancer</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cáncer de la próstata</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antigène spécifique prostate</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prostate specific antigen</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antigeno específico prostata</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Marqueur tumoral</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Tumoral marker</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Marcador tumoral</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Méthode immunologique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Immunological method</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Método inmunológico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etalonnage</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Calibration</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Contraste</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Urologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Urology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Urología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>OMS</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>WHO</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>OMS</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Matériau référence</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Reference material</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Material referencia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Homme</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Human</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Hombre</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Biochimie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Biochemistry</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Bioquímica</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Biologie moléculaire</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Molecular biology</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Biología molecular</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Total</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Total</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Total</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>22</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de la prostate</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Prostate disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Prostata patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Male genital diseases</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato genital macho patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>334</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 09-0458278 INIST</NO>
<ET>20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers</ET>
<AU>STEPHAN (Carsten); BANGMA (Chris); VIGNATI (Giulio); BARTSCH (Georg); LEIN (Michael); JUNG (Klaus); PHILIPPE (Marianne); SEMJONOW (Axel); CATALONA (William J.)</AU>
<AF>Department of Urology, Charité - Universitätsmedizin Berlin/Berlin/Allemagne (1 aut., 5 aut., 6 aut.); Department of Urology, Erasmus Medical Center and University/Rotterdam/Pays-Bas (2 aut.); Center of Endocrine and Metabolic Diseases, G. Fornaroli Hospital/Magenta/Italie (3 aut.); Department of Urology, Medical University Innsbruck/Innsbruck/Autriche (4 aut.); Berlin Institute for Urologic Research/Berlin/Allemagne (5 aut., 6 aut.); Department of Clinical Biochemistry, Cliniques Universitaires Saint-Luc/Brussels/Belgique (7 aut.); Prostate Center, University Clinic Münster/Allemagne (8 aut.); Department of Urology, Northwestern Feinberg School of Medicine/Chicago, IL/Etats-Unis (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The International journal of biological markers; ISSN 0393-6155; Italie; Da. 2009; Vol. 24; No. 2; Pp. 65-69; Bibl. 27 ref.</SO>
<LA>Anglais</LA>
<EA>Aim: To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods: Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results: All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA x 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk.</EA>
<CC>002B24O11; 002B20B02</CC>
<FD>Biologie clinique; Analyse quantitative; Forme libre; Cancer de la prostate; Antigène spécifique prostate; Marqueur tumoral; Méthode immunologique; Etalonnage; Urologie; OMS; Matériau référence; Homme; Biochimie; Biologie moléculaire; Diagnostic; Total; Cancérologie</FD>
<FG>Tumeur maligne; Cancer; Pathologie de la prostate; Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire</FG>
<ED>Clinical biology; Quantitative analysis; Free form; Prostate cancer; Prostate specific antigen; Tumoral marker; Immunological method; Calibration; Urology; WHO; Reference material; Human; Biochemistry; Molecular biology; Diagnosis; Total; Cancerology</ED>
<EG>Malignant tumor; Cancer; Prostate disease; Male genital diseases; Urinary system disease</EG>
<SD>Biología clínica; Análisis cuantitativo; Forma libre; Cáncer de la próstata; Antigeno específico prostata; Marcador tumoral; Método inmunológico; Contraste; Urología; OMS; Material referencia; Hombre; Bioquímica; Biología molecular; Diagnóstico; Total; Cancerología</SD>
<LO>INIST-21868.354000171178220010</LO>
<ID>09-0458278</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000058 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000058 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0458278
   |texte=   20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024

	Serveur d'exploration autour du libre accès en Belgique
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour du libre accès en Belgique

20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers

20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials - analysis of 1098 patients in four centers

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri